Jonathan Cohen serves as a Scientific Advisor at Pepticom, where he leverages his extensive expertise in oncology to drive innovative approaches in cancer treatment. With a robust background as a physician-researcher and head of clinical research at the Sharett Institute of Oncology at Hadassah-Hebrew University...
Jonathan Cohen serves as a Scientific Advisor at Pepticom, where he leverages his extensive expertise in oncology to drive innovative approaches in cancer treatment. With a robust background as a physician-researcher and head of clinical research at the Sharett Institute of Oncology at Hadassah-Hebrew University Medical Center, Jonathan is at the forefront of advancing cancer immunotherapy, particularly in the realm of melanoma. His dual role as a senior medical oncologist and a member of the gastro-intestinal medical oncology team allows him to integrate a multidisciplinary perspective into his advisory work at Pepticom.
At Pepticom, Jonathan is instrumental in guiding key projects that focus on the development of novel therapeutic strategies utilizing computational biology and peptide-based drug design. His deep understanding of molecular biology and cell biology informs his contributions to the company's efforts in identifying and optimizing peptide sequences that can enhance the efficacy of cancer immunotherapies. Jonathan’s experience in clinical operations and cancer research enables him to bridge the gap between laboratory discoveries and clinical applications, ensuring that Pepticom’s innovations are grounded in real-world medical needs.
Jonathan's commitment to medical education and research is evident in his collaborative approach, fostering partnerships with academic institutions and industry leaders to advance the field of oncology. His oral communication skills facilitate effective dissemination of complex scientific concepts, making him a valuable asset in both internal strategy discussions and external stakeholder engagements. Through his role at Pepticom, Jonathan Cohen is not only shaping the future of cancer treatment but also contributing to the broader dialogue on the importance of personalized medicine in oncology.
